$KZR
Kezar Life Sciences, Inc.

2020 Q4 Form 10-K Financial Statement

#000156459021012525 Filed on March 11, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.950M $3.290M $2.710M
YoY Change 14.79% 26.54% 11.52%
% of Gross Profit
Research & Development $8.120M $8.260M $7.148M
YoY Change 9.29% 16.67% 3.22%
% of Gross Profit
Depreciation & Amortization $360.0K $200.0K $300.0K
YoY Change 5.88% 0.0% 50.0%
% of Gross Profit
Operating Expenses $11.07M $11.55M $9.853M
YoY Change 10.71% 19.32% 5.32%
Operating Profit -$9.853M
YoY Change 5.32%
Interest Expense $130.0K $260.0K $353.0K
YoY Change -69.05% -50.94% -44.58%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$10.94M -$11.29M -$9.500M
YoY Change 14.2% 23.39% 8.94%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.94M -$11.29M -$9.500M
YoY Change 14.22% 23.4% 8.97%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$218.3K -$225.8K -$221.2K
COMMON SHARES
Basic Shares Outstanding 46.26M
Diluted Shares Outstanding 50.00M 42.94M

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.4M $150.0M $157.5M
YoY Change 79.54% 76.06% 68.63%
Cash & Equivalents $21.23M $12.83M $17.30M
Short-Term Investments $119.2M $137.1M $140.2M
Other Short-Term Assets $1.631M $3.900M $1.312M
YoY Change 55.63% 8.33% 13.1%
Inventory
Prepaid Expenses $2.733M $1.780M
Receivables
Other Receivables
Total Short-Term Assets $144.8M $153.8M $160.6M
YoY Change 78.49% 73.2% 66.84%
LONG-TERM ASSETS
Property, Plant & Equipment $3.435M $3.669M $3.902M
YoY Change -19.78% -56.32% -17.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $282.0K $300.0K $282.0K
YoY Change 0.0% 6.38% 0.0%
Total Long-Term Assets $7.031M $7.400M $7.760M
YoY Change -16.11% -15.17% -14.07%
TOTAL ASSETS
Total Short-Term Assets $144.8M $153.8M $160.6M
Total Long-Term Assets $7.031M $7.400M $7.760M
Total Assets $151.8M $161.2M $168.3M
YoY Change 69.63% 65.29% 59.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.358M $1.300M $1.007M
YoY Change 186.51% 57.77% 5.45%
Accrued Expenses $3.021M $3.872M $3.027M
YoY Change -28.38% 8.76% 5.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.442M $6.200M $5.045M
YoY Change 7.31% 16.39% 6.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.400M $4.700M $5.000M
YoY Change -20.0% -17.54% -15.25%
Total Long-Term Liabilities $4.400M $4.700M $5.000M
YoY Change -20.0% -17.54% -15.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.442M $6.200M $5.045M
Total Long-Term Liabilities $4.400M $4.700M $5.000M
Total Liabilities $10.86M $10.90M $10.01M
YoY Change -5.26% -1.14% -6.18%
SHAREHOLDERS EQUITY
Retained Earnings -$126.0M -$115.1M -$103.8M
YoY Change 49.53% 54.08% 58.34%
Common Stock $267.1M $262.1M
YoY Change 64.37% 63.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $141.0M $150.3M $158.3M
YoY Change
Total Liabilities & Shareholders Equity $151.8M $161.2M $168.3M
YoY Change 69.63% 65.29% 59.9%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$10.94M -$11.29M -$9.500M
YoY Change 14.22% 23.4% 8.97%
Depreciation, Depletion And Amortization $360.0K $200.0K $300.0K
YoY Change 5.88% 0.0% 50.0%
Cash From Operating Activities -$9.310M -$9.250M -$10.09M
YoY Change 29.13% 11.99% 30.87%
INVESTING ACTIVITIES
Capital Expenditures -$80.00K $0.00 -$20.00K
YoY Change 300.0% -100.0% -95.92%
Acquisitions
YoY Change
Other Investing Activities $17.41M $2.790M -$37.26M
YoY Change 924.12% -82.22% -1516.73%
Cash From Investing Activities $17.32M $2.790M -$37.28M
YoY Change 930.95% -82.14% -1842.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 310.0K 1.970M 43.99M
YoY Change 287.5% 19600.0% 24338.89%
NET CHANGE
Cash From Operating Activities -9.310M -9.250M -10.09M
Cash From Investing Activities 17.32M 2.790M -37.28M
Cash From Financing Activities 310.0K 1.970M 43.99M
Net Change In Cash 8.320M -4.490M -3.380M
YoY Change -252.66% -160.92% -37.29%
FREE CASH FLOW
Cash From Operating Activities -$9.310M -$9.250M -$10.09M
Capital Expenditures -$80.00K $0.00 -$20.00K
Free Cash Flow -$9.230M -$9.250M -$10.07M
YoY Change 28.37% 12.94% 39.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
7000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-35087000
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1779
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2020 kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P7Y
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-45000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19083826
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-23167000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.84
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10264584
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-92000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
62000
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019Q4 us-gaap Assets
Assets
89513000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2358000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
823000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3021000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4218000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1042000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
900000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6442000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6003000
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14951000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
63255000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1878000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1048000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
81132000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4282000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3314000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3817000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
282000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
282000
CY2020Q4 us-gaap Assets
Assets
151842000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1817000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4282000
CY2019 us-gaap Depreciation
Depreciation
900000
CY2018 us-gaap Depreciation
Depreciation
700000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4422000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5464000
CY2020Q4 us-gaap Liabilities
Liabilities
10864000
CY2020 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises
41000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-72000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35080000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-35087000
CY2019Q4 us-gaap Liabilities
Liabilities
11467000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46359743
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46359743
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19208077
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19208077
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
46000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
267093000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
162505000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-137000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-196000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126024000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84282000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
140978000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
78046000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
151842000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89513000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27363000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18136000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9979000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6590000
CY2018 us-gaap Operating Expenses
OperatingExpenses
24726000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
52000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-20000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
59000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
7000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41683000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23259000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-25687000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
77931000
CY2018 kzr Issuance Of Common Stock Initial Public Offering
IssuanceOfCommonStockInitialPublicOffering
77695000
CY2018 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
55000
CY2018 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises
69000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1993000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4943000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
59000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-92000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-23167000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
78046000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6748000
CY2020 kzr Stock And Pre Funded Warrants Issued During Period Net Of Offering Costs Value
StockAndPreFundedWarrantsIssuedDuringPeriodNetOfOfferingCostsValue
99161000
CY2020 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
470000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
272000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
108797000
CY2019 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
272000
CY2019 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises
50000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4007000
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
218000
CY2020 kzr Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Underwritten Offerings Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInUnderwrittenOfferingsNetOfOfferingCosts
99186000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
99642000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
272000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77913000
CY2018 kzr Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Underwritten Offerings Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInUnderwrittenOfferingsNetOfOfferingCosts
77695000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
456000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-45000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-41742000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
140978000
CY2020 us-gaap Profit Loss
ProfitLoss
-41742000
CY2019 us-gaap Profit Loss
ProfitLoss
-35087000
CY2018 us-gaap Profit Loss
ProfitLoss
-23167000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1544000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1301000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
690000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4943000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
4007000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1993000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-317000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
979000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
476000
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-106000
CY2020 kzr Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
1424000
CY2019 kzr Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
553000
CY2018 kzr Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
1136000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-61000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
313000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2208000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1440000
CY2020 kzr Increase Decrease In Operating Lease Liabilities And Other Liabilities
IncreaseDecreaseInOperatingLeaseLiabilitiesAndOtherLiabilities
-900000
CY2019 kzr Increase Decrease In Operating Lease Liabilities And Other Liabilities
IncreaseDecreaseInOperatingLeaseLiabilitiesAndOtherLiabilities
-774000
CY2018 kzr Increase Decrease In Operating Lease Liabilities And Other Liabilities
IncreaseDecreaseInOperatingLeaseLiabilitiesAndOtherLiabilities
-8000
CY2018 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
295000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36949000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29877000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20792000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
194000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
607000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1120000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
225728000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
102255000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
119244000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
169424000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
123281000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
36450000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56498000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20419000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83904000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26864000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-81000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6277000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9231000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14951000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24182000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51046000
CY2020 kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
41000
CY2018 kzr Addition Of Tenant Improvement Paid By Landlord
AdditionOfTenantImprovementPaidByLandlord
2703000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
38000
CY2018 kzr Conversion Of Redeemable Convertible Preferred Stock To Common Stock
ConversionOfRedeemableConvertiblePreferredStockToCommonStock
77931000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-5.62
CY2020 kzr Unpaid Offering Costs In Accrued Liabilities
UnpaidOfferingCostsInAccruedLiabilities
25000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 kzr Stockholders Equity Note Minimum Price Post Split
StockholdersEquityNoteMinimumPricePostSplit
15.884
CY2018Q2 kzr Stockholders Equity Note Adjusted Price Post Split
StockholdersEquityNoteAdjustedPricePostSplit
7.942
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1684000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions include the valuation of marketable securities, useful lives of fixed assets, stock-based compensation, and accrued research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.</p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also anticipate that the COVID-19 pandemic will continue to have an impact on the clinical and preclinical development timelines for our clinical and preclinical programs.  Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December 31, 2020, the majority of the </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company’s cash</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cash equivalents</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and marketable securities</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">held by financial institutions in the United States, while </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately $</span>0.1<span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">held by a financial institution in Australia. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such deposits in the United States </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in excess of insured limits</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020 kzr Reduction Of Research And Development Expenses
ReductionOfResearchAndDevelopmentExpenses
58000
CY2019 kzr Reduction Of Research And Development Expenses
ReductionOfResearchAndDevelopmentExpenses
635000
CY2018 kzr Reduction Of Research And Development Expenses
ReductionOfResearchAndDevelopmentExpenses
5000
CY2020Q4 kzr Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
766000
CY2019Q4 kzr Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
642000
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M1D
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
542000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
505000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2020Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2019Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
52208000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
4535000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
138557000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
138566000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
138557000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
138566000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
158000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
282000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6731000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3021000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4218000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1542000
CY2020 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The operating lease agreement has one option to extend the lease term for a period of five years at the fair market rate at the time of the extension.
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1267000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5464000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6177000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6099000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2742000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3435000
CY2020 us-gaap Depreciation
Depreciation
900000
CY2020Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
461000
CY2019Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
1687000
CY2020Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
929000
CY2019Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1027000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1355000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1293000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
103000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
53000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
173000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
900000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
774000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
1099000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
1099000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1588000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1635000
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
909091
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3793706
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3107066
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.19
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3151000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1042000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4422000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1503876
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5464000
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1100000
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1100000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.87
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
56653
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.95
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
185000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.14
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7134000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
65167
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.84
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4489122
CY2020Q4 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
2358197
CY2020Q4 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
5.62
CY2020Q4 kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
4627000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1000000.0
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
500000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
500000
CY2018 us-gaap Variable Lease Cost
VariableLeaseCost
400000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2020Q4 kzr Maximum Ownership Percentage Of Holders Upon Exercise Of Warrants
MaximumOwnershipPercentageOfHoldersUponExerciseOfWarrants
0.0499
CY2020Q4 kzr Maximum Ownership Percentage Allowed To Be Increased Or Decreased By Warrant Holders Upon Prior Notice
MaximumOwnershipPercentageAllowedToBeIncreasedOrDecreasedByWarrantHoldersUponPriorNotice
0.1999
CY2020Q4 kzr Class Of Warrants Or Rights Exercised
ClassOfWarrantsOrRightsExercised
0
CY2020Q1 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2020-02-04
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2020Q1 kzr Class Of Warrant Or Rights Expiration Date
ClassOfWarrantOrRightsExpirationDate
2040-02-04
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2884615
CY2020Q2 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2020-06-11
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2020Q2 kzr Class Of Warrant Or Rights Expiration Date
ClassOfWarrantOrRightsExpirationDate
2040-06-11
CY2020 kzr Period For Right To Purchase Underlying Option Shares Lapses After Applicable Vesting Commencement Date
PeriodForRightToPurchaseUnderlyingOptionSharesLapsesAfterApplicableVestingCommencementDate
P1Y
CY2019Q4 kzr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
1336000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4943000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4007000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1993000
CY2020 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10985000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2938000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30575000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21555000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2177000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1194000
CY2020Q4 kzr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
1148000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13188000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29410000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20196000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-41742000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-35087000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-23167000
CY2015Q4 kzr Research And Development Tax Credit Maximum Utilization Against Employers Portion Of Payroll Tax
ResearchAndDevelopmentTaxCreditMaximumUtilizationAgainstEmployersPortionOfPayrollTax
250000
CY2020 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
373000
CY2019 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
284000
CY2018 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
175000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.009
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.064
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.002
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.027
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.017
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.026
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.019
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.014
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.220
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.223
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.292
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1665000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1056000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1009000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24824000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16986000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12560000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1165000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-9579000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1359000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
628000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
469000
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
557000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
628000
CY2020Q4 kzr Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
696000
CY2019Q4 kzr Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
802000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9200000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7600000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5100000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
900000
CY2020Q4 kzr Liability Related To Uncertain Tax Position
LiabilityRelatedToUncertainTaxPosition
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
381000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
487000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
868000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44004190
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19083826
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10264584
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.84
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.26
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4497981
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3137093
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2270723
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
10478000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
9853000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
11551000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
11068000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10012000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9500000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11289000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-10941000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
8309000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
9355000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
9681000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
9997000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7642000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-8718000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-9148000

Files In Submission

Name View Source Status
0001564590-21-012525-index-headers.html Edgar Link pending
0001564590-21-012525-index.html Edgar Link pending
0001564590-21-012525.txt Edgar Link pending
0001564590-21-012525-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ggzs2zmnpwip000001.jpg Edgar Link pending
kzr-10k_20201231.htm Edgar Link pending
kzr-10k_20201231_htm.xml Edgar Link completed
kzr-20201231.xsd Edgar Link pending
kzr-20201231_cal.xml Edgar Link unprocessable
kzr-20201231_def.xml Edgar Link unprocessable
kzr-20201231_lab.xml Edgar Link unprocessable
kzr-20201231_pre.xml Edgar Link unprocessable
kzr-ex109_8.htm Edgar Link pending
kzr-ex231_11.htm Edgar Link pending
kzr-ex311_7.htm Edgar Link pending
kzr-ex312_6.htm Edgar Link pending
kzr-ex321_12.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending